Biomax, Pierre Fabre Collaborate
News Jun 19, 2015
Using the BioXM Knowledge Management Environment, Biomax created the antibody knowledgebase, which offers sequence analysis and storage capabilities, infrastructure for sharing in-house data and algorithms, a collection of public data, and includes both public and third-party algorithms.
Following a successful pilot project, Pierre Fabre has licensed Biomax's BioXM Knowledge Management Environment and agreed to work with the company to further develop and expand the system.
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Combination Drug Trial Launched to Eradicate B-Cell MalignanciesNews
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.READ MORE
Monoclonal Antibodies Crucial to Fighting Emerging Infectious DiseasesNews
A new article outlines the potential uses for mAbs as treatments for infectious diseases and as a prevention tool for protecting individuals at risk of infection and slowing disease outbreaks.READ MORE